Methodology and Evidence Review 1005 1.2. Organization of the GWC 1005 1.3. Review and Approval 1005 2. Culprit Artery Only Versus Multivessel PCI 1005 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) Appendix 2. Author Relationships With Industry and Other Entities (Relevant) Appendix 3. Reviewer Relationships With Industry and Other Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction (Combined Peer Reviewers From *Writing committee members are required to recuse them- selves from voting on sections to which their specific relation- ships with industry may apply; see Appendixes 1 and 2 for detailed information. ACC/AHA Representative. SCAI Representative. ACC/AHA Task Force on Clinical Practice Guidelines Liaison. || Dr. Deborah D. Ascheim accepted a position at Capricor Therapeutics in August 2015, after the writing effort was com- pleted. In accordance with ACC/AHA policy, she recused her- self from the final voting process. ACP Representative. # ACEP Representative. **Former Task Force member; current member during the writing effort. This document was approved by the American College of Cardiology Board of Trustees and Executive Committee, the American Heart Associa- tion Science Advisory and Coordinating Committee, and the Society of Cardiovascular Angiography and Interventions in September 2015, and by the American Heart Association Executive Committee in October 2015. The online-only Comprehensive RWI Data Supplement table is available with this article at http://circ.ahajournals.org/lookup/ suppl/doi:10.1161/CIR.0000000000000336/-/DC1. The online-only Data Supplement is available with this article 000000336/-/DC2. 